Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: Economic analysis of a randomised trial in 20 536 individuals

Lancet

Volumn 365, Issue 9473, 2005, Pages 1779-1785

  Mihaylova, Borislava ^a   Briggs, Andrew ^a   Armitage, Jane ^a   Parish, Sarah ^a   Gray, Alastair ^a   Collins, Rory ^a   Collins, R ^a   Meade, T ^a   Sleight, P ^a   Peto, R ^a   Youngman, L ^a   Buxton, M ^a   De Bono, D ^a   George, C ^a   Fuller, J ^a   Keech, A ^a   Mansfield, A ^a   Pentecost, B ^a   Simpson, D ^a   Warlow, C ^a   McNamara, J ^a   O'Toole, L ^a   Doll, R ^a   Wilhelmsen, L ^a   Fox, K M ^a   Hill, C ^a   Sandercock, P ^a   more..

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; SIMVASTATIN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DRUG COST; ECONOMIC ASPECT; FEMALE; HOSPITAL COST; HOSPITALIZATION; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; UNITED KINGDOM;

EID: 84979726213     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)63014-0     Document Type: Article

References (23)

1. MRC/BHF Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experience Eur Heart J 20 1999 725 741
2. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial Lancet 360 2002 7 22
3. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial Lancet 361 2003 2005 2016
4. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin on stroke and other major vascular events in 20 536 people with cerebrovascular disease or other high risk conditions Lancet 363 2004 757 767
5. NHS Executive Trust financial returns 2001 NHS Executive Leeds
6. NHS Executive Trust financial returns 2002 NHS Executive Leeds
7. Joint Formulary Committee British National Formulary 41 2001 British Medical Association and Royal Pharmaceutical Society of Great Britain London
8. Prospective Studies Collaboration Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies Lancet 360 2002 1903 1913
9. EC Fieller Some problems in interval estimation J R Stat Soc (Series B) 16 1954 175 183
10. B Efron, R Tibshirani An introduction to the bootstrap 1993 Chapman & Hall New York
11. UK Prospective Diabetes Study Group Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40 BMJ 317 1998 720 726
12. Zocor datasheet http://www.emc.medicines.org.uk/emc/assets/c/html/ DisplayDoc.asp?DocumentID=1201 (accessed Feb 28, 2005)
13. AD Sniderman Is there value in liver function test and creatine phosphokinase monitoring with statin use? Am J Cardiol 94 suppl 2004 30F 34F
14. Department of Health Prescription cost analysis: England 2003 2004 Department of Health London http://www.publications.doh.gov.uk/stats/pca2003.htm (accessed March 23, 2005)
15. Department of Health The government's expenditure plans: departmental report 2003 http://www.dh.gov.uk/PublicationsAndStatistics/Publications/ AnnualReports/DHAnnualReportsArticle/fs/en?CONTENT_ID=4008345&chk=c1v99p (accessed March 23, 2005)
16. PP Glasziou, SD Eckermann, SE Mulray Cholesterol-lowering therapy with pravastatin in patients with average cholesterol levels and established ischaemic heart disease: is it cost-effective? Med J Aust 177 2002 428 434
17. B Jonsson, M Johannesson, J Kjekshus, AG Olsson, TR Pedersen, H Wedel Cost-effectiveness of cholesterol lowering: results from the Scandinavian Simvastatin Survival Study (4S) Eur Heart J 17 1996 1001 1007
18. J Caro, W Klittich, A McGuire The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin BMJ 315 1997 1577 1582
19. B Jonsson, JR Cook, TR Pedersen The cost-effectiveness of lipid lowering in patients with diabetes: results from the 4S trial Diabetologia 42 1999 1293 1301
20. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, British Diabetic Association Joint British recommendations on prevention of coronary heart disease in clinical practice: summary BMJ 320 2000 705 708
21. Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) JAMA 285 2001 2486 2497
22. Prescription Pricing Authority NHS electronic drug tariff http://www.ppa.org.uk/edt/May_2005/mindex.htm (accessed May 4, 2005)
23. Tamro Interim report January-June 2003 http://www.tamro.com/ interimreports/2003q2/pdf/tamro_january_june_2003_print.pdf (accessed Feb 28, 2005)